News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Active Biotech AB’s Novel Cancer Treatment ANYARA Shows Pharmacological Proof Of Concept After Successful Phase I Studies
December 13, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN -- (MARKET WIRE) -- December 13, 2006 -- Ongoing initiation of a combined Phase II/III study in renal cancer at 45 sites in Europe
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Europe
MORE ON THIS TOPIC
Insights
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
July 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
China
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
July 27, 2026
·
10 min read
·
Heather McKenzie
CAR-T
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
July 27, 2026
·
8 min read
·
Tristan Manalac
Drug Development
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
July 24, 2026
·
3 min read
·
Gabrielle Masson
